Pazopanib Hydrochloride

盐酸培唑帕尼

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NamePazopanib Hydrochloride
Drug Alias Namepazopanibum培唑帕尼帕佐帕尼盐酸帕唑帕尼帕唑帕尼 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptor 3 antagonistsVascular endothelial growth factor receptor 3 antagonistsFibroblast growth factor receptor 1 antagonists +[11] 
TargetsVascular endothelial growth factor receptor 1Stem cell growth factor receptorVascular endothelial growth factor receptor 3 +[11] 
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Skin MelanomaGastroenteropancreatic neuroendocrine tumor +[85] 
Global Approved IndicationsCarcinoma, Renal CellSarcoma
Approved Indications in ChinaCarcinoma, Renal Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2009/10/19
Country/TerritoryCzechiaBelgiumCanada +[52] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline PlcNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcNovartis Pharma Schweiz AgNovartis Pharma Ag +[9] 
Inactive CompaniesUtah State UniversityDana-Farber Cancer InstituteRadboud University Medical Center +[19] 
Active IndicationsGastroenteropancreatic neuroendocrine tumorSolid tumoursChondrosarcoma, Extraskeletal Myxoid +[11] 
Inactive IndicationsMedullary thyroid cancer (MTC)Skin MelanomaHormone-Resistant Prostate Neoplasms +[74] 

Other Information

ATC CodeL01EX03
Related LinksWikipediaDrugBankKEGG